Many more targeted therapies are now available for people with AML, in both the newly diagnosed and relapsed/refractory settings. Find out more about the genetic and protein targets, and their associated therapeutics, in this review.
Rapidly progressive insulin-dependent diabetes in the absence of islet autoantibodies developed two years after starting treatment with the immune checkpoint inhibitor nivolumab.
Women with a new diagnosis of high-risk, locally advanced cervical cancer could benefit from the addition of pembrolizumab to standard chemoradiotherapy.
A case of extreme hypotension that could have been prevented or mitigated with awareness of the underlying hypothyroidism related to nivolumab treatment.
Although circulating tumor DNA analysis has not been adopted as widely in gynecologic cancers as in other tumor types, new research shows promise for diagnosis, prognosis, and prediction of recurrence.
Our tailored content service will keep you up to date…
Receive newsletters curated for the busy specialist by our expert editorial team
How do nutrition, supplements and antibiotics impact patient outcomes?
Recent research suggests that the gut microbiome could be an important modulator of response to CAR T-cell therapy in patients with hematologic cancers.
Prof. Marion Subklewe takes us through the latest evidence, highlighting the impact of antibiotics, nutrition, and dietary supplements, and discusses how to devise interventions to improve patient outcomes.
Rapidly progressive insulin-dependent diabetes in the absence of islet autoantibodies developed two years after starting treatment with the immune checkpoint inhibitor nivolumab.
A case of extreme hypotension that could have been prevented or mitigated with awareness of the underlying hypothyroidism related to nivolumab treatment.
The first case of severe megaloblastic anemia in a patient treated with erlotinib for advanced NSCLC. It highlights the need for close clinical and blood monitoring in people receiving long-term TKI therapy.
Live: Monday 10 June 2024, from 16:30 – 18:00 (CEST)
In this live interactive webinar, a multidisciplinary team of speakers will provide practical guidance on managing patients with cutaneous T-cell lymphoma. Learn about the key aspects of diagnosis and treatment via a series of patient cases.
Follicular lymphoma (FL), the most common indolent B-cell lymphoma, develops over decades before manifesting as overt disease. BCL2 overexpression by t(14;18) confers a survival advantage to B cells during the germinal center reaction, and …
Among various reasons for a rise in surgical referrals for locally advanced non-small cell lung cancer, few are improved clinical-pathological staging, better understanding of oncological driver mutation, and aggressive neoadjuvant treatment …
Primary breast carcinomas are largely of ductal or lobular histology; however, there are a myriad of other subtypes less commonly seen. While most breast cancers do fit within these two primary groupings, patients may present with unique subtypes …
Despite enormous efforts being invested in the development of novel therapies for brain malignancies, there remains a dire need for effective treatments, particularly for pediatric glioblastomas. Their poor prognosis has been attributed to the …
Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.
The ADAURA trial has, as of this year, demonstrated an overall survival benefit with the adjuvant use of osimertinib in people with resectable NSCLC.
We take an in-depth look at the study with Dr. Luis Paz-Ares, who outlines the study findings, discusses the clinical implications, and addresses the pertinent questions raised by the trial.
A series of patient cases underpin this live interactive webinar that aims to provide practical guidance on a multidisciplinary approach to managing patients with cutaneous T-cell lymphoma.
Identifying molecular biomarkers is crucial in determining the best targeted treatment options for your patients with advanced thyroid cancer.
Join our expert-led multi-format educational program that explores the continuing discovery of new genomic targets and delivers the latest research in molecular testing and the application of targeted therapies for thyroid cancer.
Expert-led, multiformat program which will address the individualized management of NSCLC, through education on the detection of NTRK gene fusions, current evidence-based guidelines, and new and emerging therapies. Will also include guidance on integrating shared decision making into your clinical practice, drawing on insights from a patient on how best to communicate.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an important therapy for patients with T-cell lymphomas, including cutaneous T-cell lymphoma (CTCL), adult T-cell lymphoma (ATL), and peripheral T-cell lymphoma (PTCL).
In 2022, the World Health Organization ranked the incidence of gastric cancer as third and fifth most in China and worldwide, respectively, with incidence and mortality rates accounting for 10.6% and 12.5% of cancer cases in China, for 5.6% and …
Neuroblastoma (NB) is the most common extracranial solid tumor in children and accounts for 15% of childhood cancer-related deaths [ 1 ]. At the time of diagnosis, approximately 50% of patients have lymph node, liver, and bone marrow metastases …
The identification of actionable biomarkers and development of targeted therapies have revolutionized the field of lung cancer treatment. In patients with advanced non-small cell lung cancer (NSCLC), biomarker testing can inform selection of …
Many more targeted therapies are now available for people with AML, in both the newly diagnosed and relapsed/refractory settings. Find out more about the genetic and protein targets, and their associated therapeutics, in this review.
Women with a new diagnosis of high-risk, locally advanced cervical cancer could benefit from the addition of pembrolizumab to standard chemoradiotherapy.